Aquestive Therapeutics/AQST

$3.95

1.02%
-
1D1W1MYTD1YMAX

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Ticker

AQST

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Barber

Employees

135

Headquarters

Warren, United States

AQST Metrics

BasicAdvanced
$333.13M
Market cap
-
P/E ratio
-$0.14
EPS
2.91
Beta
-
Dividend rate
$333.13M
2.91162
$6.23
$1.15
2.29M
2.238
1.868
-13.75%
-27.78%
6.586
6.09%
87.38%
3.33%

What the Analysts think about AQST

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
127.85% upside
High $12.00
Low $7.00
$3.95
Current price
$9.00
Average price target

AQST Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.36% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$13.2M
1.54%
Net income
$-8.1M
305%
Profit margin
-61.36%
298.96%

AQST Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 50%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.11
-$0.10
-$0.03
-$0.12
-
Expected
-$0.19
-$0.12
-$0.11
-$0.08
-$0.08
Surprise
-158.2%
-15.25%
-73.5%
50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Aquestive Therapeutics stock?

Aquestive Therapeutics (AQST) has a market cap of $333.13M as of April 15, 2024.

What is the P/E ratio for Aquestive Therapeutics stock?

The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of April 15, 2024.

Does Aquestive Therapeutics stock pay dividends?

No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Aquestive Therapeutics dividend payment date?

Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.

What is the beta indicator for Aquestive Therapeutics?

Aquestive Therapeutics (AQST) has a beta rating of 2.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Aquestive Therapeutics stock price target?

The target price for Aquestive Therapeutics (AQST) stock is $9, which is 127.85% above the current price of $3.95. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Aquestive Therapeutics stock

Buy or sell Aquestive Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing